Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears 
Australia’s December Trade Surplus Expands but Falls Short of Expectations 
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals 
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Asian Markets Slip as AI Spending Fears Shake Tech, Wall Street Futures Rebound 
Celltrion Inc., a biopharmaceutical company headquartered in Incheon, South Korea, is merging with its Celltrion Healthcare subsidiary in an effort to strengthen its business synergy or combined effort. The biosimilar producer and its biosimilar marketing unit are set to be consolidated this year.
Seo Jung Jin, Celltrion Group’s chairman, said on Thursday, Aug. 17, that once Celltrion is incorporated with Celltrion Healthcare, the newly-formed entity will also take in Celltrion Pharma. The chairman said this integration will eventually happen later but did not provide an exact time frame. After all the mergings, Celltrion, Celltrion Healthcare, and the company’s chemical pharma producer will work together as one.
According to The Korea Times, Celltrion revealed its plan to acquire Celltrion Healthcare during the company’s recent regulatory filing. The changes will also entail the issuance of new shares of Celltrion to shareholders of Celltrion Healthcare, and the merger ratio is expected to stand at 1:0.4492620.
It was mentioned that the Celltrion chairman holds a 95% stake in Celltrion Holdings which in turn holds a 20.02% stake in Celltrion. The holdings also have a 35.54% stake in Celltrion Healthcare and a 54.96% stake in Celltrion Pharm.
"Celltrion is expected to complete the merger of Celltrion Healthcare by the end of the year, followed by the next merger with Celltrion Pharm in the next six months," Seo Jung Jin shared during an online conference.
The Celltrion Group said it will merge the mentioned companies, but the plan still needs the approval of shareholders. This may be completed on October 23 at the shareholders' meeting. Celltrion and Celltrion Healthcare will eventually be dissolved after the merger.
To date, while the merger is still being processed, The Korea Herald reported that Celltrion is focusing on producing and developing bio-pharmaceutical products while Celltrion Healthcare is working more on selling these products.
Photo by: Celltrion Press Room
